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ABSTRACT
This study was conducted to investigate the expression of p16 and pKi-67 in normal, preneoplasia and neoplasia lesions
of the uterine cervix. One hundred and thirty one cervical specimens, consisting of normal cervix (n = 43), cervical
intraepithelial neoplasia (CIN) lesions (n = 40) [16 LSIL: CIN 1 and 24 HSIL: 9 CIN 2 and 15 CIN 3] and cervical
squamous cell carcinomas (n = 48) [16 SCC I, 17 SCC II, 7 SCC III and 8 SCC IV] were examined immunohistochemically
in paraffin sections. All samples of the normal cervix were negative for p16. Immunoreactivity of p16 was observed in 4/
16 LSIL, 12/24 HSIL and 30/48 SCC. In all p16-positive samples, both nuclear and cytoplasmic staining were observed.
High expression of p16 (> 50 % of cell stained) was found in HSIL and SCC. Ki-67 index was significantly (p < 0.05)
higher in high-grade squamous intraepithelial lesions (HSIL: CIN 2 & 3) and SCC lesions when compared to normal
cervices. The expression of p16 and Ki-67 proliferation profile (< or > 30 % stained cells) were significantly associated
with the grade of lesions (χ2 = 6.832, p = 0.033 and χ2 = 10.952; p = 0.012 respectively). There was no significant
relationship demonstrated between p16 positivity and Ki-67 proliferation profile (χ2 = 0.292; p = 0.589). Our results
indicated that p16 protein may be involved in the carcinogenesis of cervical cancer. However, overexpression of p16
seemed to have no effect on cell proliferation. The expression of p16 and pKi-67 may be useful in cases where it is
difficult to make a diagnosis by histology.
INTRODUCTION
Eukaryotic cell cycle progression is controlled through a
complex mechanism involving the coordinated expression
and post-translational modification (e.g. phosphorylation)
of cell cycle regulating proteins. Among these proteins,
the cyclin-dependent kinase (CDK) inhibitor p16 plays a
crucial role in retinoblastoma (pRb)-mediated control of
the G1-S-phase transition of the cell cycle [1].
p16 is a tumor suppressor protein that inhibits CDK4
and CDK6, which phosphorylates pRb and subsequently
releasing the transcription factor E2F. A reciprocal relation
between p16 and pRb expression has been observed,
suggesting the presence of a negative feedback loop
allowing pRb to limit the concentration of p16 [2]. However,
the regulatory pathway is disrupted by the human papilloma
virus (HPV) oncoprotein E7, which is known to bind and
inactivate pRb. E2F is subsequently released from pRb-
E2F complex hence allowing the cell to enter the S phase
[2]. E2F accumulation may also lead to induction of p16 [2].
Many studies have proposed p16 as a biomarker and an
additional screening tool for cervical lesions [3-5].
pKi-67 is expressed during all phases of cellular cycle
(G1, S, G2 and M of proliferating cells), but is absent in
quiescent cells (G0). It is therefore a reliable biomarker of
cellular proliferation which can be determined
immunohistochemically [6]. The study aim was to identify
biomarkers of cellular proliferation in cervical lesions by
detecting the expression of p16 and pKi-67 in CIN and SCC
samples. We also investigated whether the expression of
p16 has an effect on cell proliferation, which is indicated
by the expression of pKi-67.
MATERIALS AND METHODS
A total of 131 cases of various cervical lesions were
obtained from the Pathology Department, Universiti
Kebangsaan Malaysia Medical Centre (UKMMC). The
study was approved by the Ethics Committee of UKMMC.
Samples included 43 normal cervices, 40 cases of cervical
intraepithelial neoplasia (CIN), and 48 cases of squamous
cell carcinoma (SCC) of the cervix. The normal cervical
tissues were obtained from women who underwent
hysterectomy for benign diseases. The 40 cases of CIN
included 16 of low grade squamous intraepithelial lesion
(LSIL: CIN 1) and 24 high grade squamous intraepithelial
lesions (HSIL: 9 of CIN 2, and 15 of CIN 3). Tumors were
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staged according to the International Federation of
Gynecology and Obstetrics (FIGO) criteria [7]. Sixteen
patients had FIGO stage I, 17 patients had FIGO stage II, 7
patients had FIGO stage III and 8 patients had FIGO stage
IV. All samples obtained included cervical biopsies and
surgically resected specimens that were fixed in 10% neutral
buffered formalin and embedded in paraffin blocks. For
each tissue specimen, several 3 µm sections were cut for
hematoxylin and eosin (H&E) and immunohistochemical
staining.
IMMUNOHISTOCHEMICAL STAINING
Sequential tissue sections (3 µm) were mounted on poly-L-
lysine coated slides. Archival samples were dewaxed by
gradual washings in xylene, and then dehydrated in various
concentrations of alcohol (100%, 80%, 60% and 40%). Slides
were then incubated in 3% hydrogen peroxide in distilled
water to quench endogenous peroxidase activity and this
was followed by washing in running water. Antigen
retrieval was performed by incubating slides in a preheated
coplin jar containing Target Retrieval Solution (TRS) at pH
6 (Dako, Denmark) for 20 minutes in a water bath with
temperature ranging from 95-99°C. After thermal treatment,
the jar with TRS and slides were allowed to cool for 20
minutes at room temperature. Slides were then washed in
running water for 3 minutes and were placed in Tris buffer
saline (TBS) pH 7.6. Sections were then incubated for 35
minutes with respective primary monoclonal antibodies:
anti-p16 (clone E6H4, Dako, Denmark) at a 1:50 dilution,
anti-pKi-67 (clone Mib-1, Dako, Denmark) at 1:50 dilution.
Reaction products were visualized with biotin-labeled
secondary antibody and streptavidin-peroxidase
complexes (LSAB® + HRP kit, Dako, Denmark).
Diaminobenzidine (DAB) was used as a chromogenic
substrate to visualize the antibody-antigen reaction. All
sections were then counterstained with hematoxylin and
mounted with permanent mountant DPX. Sections were
visualized under light microscopy for assessment of
immunoreactivity. Cervical carcinoma tissue known to be
positive for p16 expression was included as positive
control, while tonsil tissue was used as positive control for
pKi- 67 immunostaining. Each positive control was
consistently positive. Negative controls for p16 and Ki-67
were obtained by substituting the primary antibody with
TBS. Negative control sections were unstained.
IMMUNOSTAINING ASSESSMENT
A researcher without knowledge of clinicopathologic data
of the samples evaluated all slides for immunostaining in a
blind fashion. Confirmation of the diagnosis was done by
a pathologist who evaluated the same slides independently.
Most of the slides (95%) were classified similarly by both
investigators. Discrepancies were resolved by reevaluation
and discussion. Cases were included only when there was
agreement by both investigators. Staining of p16 was
observed in both nuclei and cytoplasm, while
immunoreactivity of pKi-67 was observed in the cells with
a distinct brown stain confined to the nuclei. In the p16
immunoreactivity assessment, the percentage of positive
dysplastic or tumor cells was scored according to the
method by de Putte et al. [8] and Ishikawa et al. [9]. When
none or less than 5% of dysplastic or tumor cells were
stained, it is regarded as negative; when 5-50% cells were
stained, it is regarded as 1+; and when more than 50 % cells
were stained, it is regarded as 2+. The number of pKi-67
stained nuclei was obtained by counting 200 cells in X400
magnification field for each sample, including all of the
epithelial layers. After counting a total of 200 cells, the
immunoreactive score was expressed as a percentage of
the total cell count or Ki-67 index. The cutoff level to define
high and low proliferating tumors was 30% [10, 11].
STATISTICS
Chi-square test was used to evaluate differences in p16
staining, which were analyzed as qualitative variables.
However, the mean and standard error of mean (SEM) of
the Ki- 67 index were compared using one-way analysis of
variance (ANOVA). A p value less or equal to 0.05 was
considered statistically significant. Statistical analyses were
performed using SPSS 11.0.
RESULTS
Negative staining of p16 was observed in normal squamous
epithelium. Diffuse cytoplasmic and nuclear staining was
observed in 16/24 (40%) of CIN cases and 30/48 (62.5%) of
SCC cases (Figure 1). Expression of pKi-67 was mainly
present in the parabasal rather than in the basal layer of
normal epithelium (Figure 2a). In CIN 3, pKi-67 staining
was diffusely present in the nuclei of dysplastic epithelium
and mitotic cells (M) (Figure 2d, e). Diffuse nuclear staining
for pKi-67 in most tumor cells of SCC was also observed
(Figure 2f). The results of p16 and pKi-67 immunostaining
of cervical lesions are summarized in Figure 3. All normal
cases were negative for p16 immunostaining. All p16-
positive cases in LSIL (25%; 4/16) were scored at 1+. More
cases of p16 immunopositivity were observed in HSIL; 8%
(2/24) were scored 1+ and 42 % (10/24) were scored 2+.
Overexpression of p16 was also observed in majority of
the SCC cases (62.5%; 30/48), where 12.5% (6/48) were
scored 1+ and 50% (24/48) were scored 2+ (Figure 3a).
Majority of pKi-67 immunopositivity in normal cases (96%;
27/28) exhibited low proliferation index with mean index of
10.32 + 1.00%. High proliferation capacity was observed in
LSIL (6%; 1/16), HSIL (17%; 4/24) and SCC (10%; 5/48)
cases (Figure 3b). Mean pKi-67 proliferation index in LSIL,
HSIL and SCC were 24.75 + 4.96%, 27.50 + 8.50% and 26.00
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+ 6.92%, respectively. HSIL and SCC showed significantly
higher Ki-67 index when compared to normal (ANOVA: F =
3.940; p = 0.013). The association between the expression
of immunohistochemical markers and grade of the lesions
is shown in Table 1. The expression of p16 and pKi-67
proliferation index were significantly associated with the
grade of the cervical lesions (p = 0.033 and p = 0.012
respectively). We did not find any significant relationship
between overexpression of p16 and pKi-67 proliferation
profile (χ2 = 0.292; p = 0.589) (Table 2).
DISCUSSION
Several previous studies demonstrated strong
immunohistochemical expression of p16 in both high risk
squamous intraepithelial lesions and SCC of the cervix [1,
5, 12]. One possible explanation of p16 overexpression may
be inactivation of pRb by HPV E7 [13]. Although p16 is
present in high concentration in these cases, it has no
inhibitory effect on the cell cycle because pRb has already
been blocked by the E7 oncoprotein. The majority of HPV
infections is transient and regresses spontaneously.




Figure 1. Immunoreactivity of p16 INK4a in cervical tissues (a)
Normal epithelium, negative (X100) (b) CIN 1, weak
expression (score 1+) of p16 INK4a (X200) (c) CIN 2, positive
score 1+ (X200) (d) CIN 3, positive score 2+ (X100), and (e)
SCC (X200), exhibiting diffuse nuclear and cytoplasmic
expression of p16 INK4a, in more than 50 % of cells (score 2+)
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Figure 2. Immunohistochemical expression of pKi-67 in cervical tissues (a) Normal cervical epithelial cells: pKi-67 positive
cells were mainly present in the parabasal layer (b) CIN 1 (c) CIN 2 (d) CIN 3: Nuclear staining appears at all levels of the
dysplastic epithelium (e) Mitotic cell (M) showed immunopositivity of Ki-67, (f) SCC:  Intense nuclear staining in tumor
cells (X 400 magnification)
already advanced interference of the viral oncoproteins
with cellular proteins involved in cell-cycle regulation [14].
A study by Negri et al. [4] found an association
between overexpression of p16 in LSIL and high-risk HPV
infection. They reported that LSIL cases with diffuse p16
staining had a significantly higher tendency to progress to
high-grade lesions compared to p16-negative cases, and
hence its expression may serve as a marker of progression
in early lesions of the cervix uteri. It has also been suggested
that p16 may be a useful adjunct in the diagnosis of CIN in
sections of cervical biopsy samples or cervical smears [4,
5, 12]. In our study, p16 expression was not seen in normal
cervix or in non-dysplastic tissue. p16 expression was
observed in LSIL and the intensity of expression was higher
in HSIL and highest in SCC. p16 immunopositivity was
seen in both nuclear and cytoplasm of the dysplastic or
tumor cells. Our results are in concordance with other
studies [4, 12, 13, 15]. According to the report by Murphy
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Figure 3. Distribution of p16 expression level (A) and pKi-67 proliferation index (B) according to cervical lesions grades
Table 1. The association between the expression of immunochemicals markers and grade of lesions
Number of cases (%)
Normal LSIL HSIL SCC
p16 immunoreactivitya
Negative 43 (100) 12 (75) 12 (50) 18 (38)
Positive 0 (0) 4 (25) 12 (50) 30 (62)
Total 43 (100) 16 (100) 24 (100) 48 (100)
pKi-67 proliferation indexb
Negative 15 (34) 12 (75) 16 (66) 33 (69)
Low (< 30 %) 27 (63) 3 (19) 4 (17) 10 (21)
High (> 30 %) 1 ( 3) 1 (6) 4 (17) 5 (10)
Total 43 (100) 16 (100) 24 (100) 48 (100)
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et al. [12], p16 expression was observed to be low at both
mRNA and protein level. Hence, p16 may only be detectable
when it is upregulated, especially in cervical neoplastic
lesions. Overexpression of p16 is usually observed in the
nucleus; however its presentation in the cytoplasm may
be due to of post-transcriptional modification [12].
Mutation of p16 is a rare event involved in cervical cancer
development. Munirajan et al. [16] did not find any mutation
or/and deletion of p16 gene in their cervical cancer patients
studied. Therefore, inactivation of pRb by HPV E7 protein
has been hypothesized to contribute to the overexpression
of p16 in cervical lesions. However, there was a limitation
in this study as there was no HPV data available for all
cases enrolled in this study. Further verification of HPV
involvement in the p16/CDK4/cycD1/pRb cell cycle
regulatory pathway cannot be elucidated in our study, but
what we have demonstrated is the possible potential of
p16 as a marker for CIN lesions and cervical cancer as its
expression was significantly associated with the increasing
grade of the lesions. In our study, only 25% of LSIL, 50%
HSIL and 62.5% of SCC cases showed immunopositivity
of p16. Our findings differed from that of Murphy et al.
[12], where they found all of the CIN and SCC cases studied
showed overexpression of p16, with a sensitivity of 99.9 %
and a specificity of 100%. Although the number of p16
positively stained cases was lower in our study, we observed
the difference in intensity of p16 expression between LSIL,
HSIL and SCC. Most of the p16 positive LSIL cases showed
low intensity (less than 50% positive cells) whereas a high
intensity (more than 50 % positive cells) immunostaining
was observed in HSIL and SCC cases. The high intensity
of p16 immunoreactivity was found to be distributed at all
layers of the dysplastic epithelium and was unique for HSIL.
A similar finding was described by Yildlz et al. [17],
suggesting the potential use of p16 to differentiate HSIL
from LSIL. However due to lack of overexpression p16 in
most cases of dysplasia and neoplasia, we suggest that
immunostaining of p16 is not an appropriate marker to
identify if an individual is at risk for cervical cancer.
On the other hand, the Ki-67 index has been used in
several studies to relate with the proliferative capacity of
cancer cells. Ki-67 labelling index of less than 10% reflects
a benign process [10] particularly inflammation and reactive
repair mechanism [18]. It was also found that Ki-67 labeling
index of more than 30% was highly predictive of malignant
or premalignant lesions [10]. In our study, the majority of
normal squamous epithelium (97%) possesses negative or
low proliferation activity suggesting that the squamous
epithelium controls its cell number by differentiation [19].
The single sample from a normal cervix was found to have
a high proliferation index which may be attributed to the
reactive type of benign disease. As reported by Walts et al.
[20], benign and reactive tissues may show up to 25% of
cells stained with pKi-67. High pKi-67 proliferation capacity
(Ki-67 index > 30%) was observed during the development
of preneoplastic and neoplastic lesions, suggesting a
decrease in differentiation but an increase in proliferation
as the lesions progress as suggested by Nam et al. [19]. In
addition, overexpression of pKi-67 is also regarded as an
indicator of biological aggressiveness [21] . In this study,
we found that the cell proliferation profile (low or high) is
associated with the grade of the cervical lesions. Our data
suggest that the progression in the uterine cervix is
accompanied by increased cellular proliferation. A similar
finding was demonstrated by Herbsleb et al. [22] and
Queiroz et al. [1]. This may suggests the possible role of
pKi-67 as a biomarker in the grading of cervical lesions.
In our study, there was no significant correlation
between p16 expression and expression of pKi-67,
suggesting that p16 expression may not have an effect on
cell proliferation. This finding was contradictory to other
studies which [22, 1, 17] suggested p16 overexpression
might induce a progressive increase in cell proliferation.
They also identified the co-localization of p16 and pKi-67
in CIN cases and suggested this finding as an independent
sign for dysplasia.
In conclusion, we observed an increase in expression
of p16 and pKi-67 during the progression of cervical cancer
in our cohort of patients, however there was no correlation
between these two markers. Both p16 and pKi-67 are
essential markers that are useful in the grading of cervical
lesions. However, caution is advised on interpreting their
expressions, where the lack of p16 and pKi-67 expression
does not always represent low risk for progression to HSIL
and SCC.
Table 2. Relationship between p16 expression and Ki-67 proliferation index
Number of cases
Ki-67 proliferation index Total
Low (< 30 %) High (> 30 %)
p16 Immunoreactivity
Negative 3 1 4
Positive 14 9 23
Total 17 10 27
Note: χ2 = 0.292; p = 0.589
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